THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) IS NOT AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY ORDINARY SHARES OR OTHER SECURITIES OF THE COMPANY AND NEITHER THIS ANNOUNCEMENT NOR ANYTHING HEREIN FORMS THE BASIS FOR ANY CONTRACT OR COMMITMENT WHATSOEVER. ORDINARY SHARES OR OTHER SECURITIES OF THE COMPANY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OF AMERICA ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION AND THE ORDINARY SHARES DESCRIBED HEREIN WILL BE SOLD IN ACCORDANCE WITH ALL APPLICABLE LAWS AND REGULATIONS.
1 October 2015
NetScientific plc
(the "Company")
Proposed Placing to raise approximately £18.0 million
Additional Fundraising to raise up to approximately £2.0 million
Proposed waiver of Rule 9 of The City Code on Takeovers and Mergers (the "Code")
Notice of General Meeting
NetScientific plc (AIM:NSCI), a transatlantic biomedical healthcare group with a differentiated investment strategy focused solely on digital health, diagnostics and therapeutics, announces a conditional Placing to raise approximately £18.0 million before expenses and an Additional Fundraising to raise up to approximately £2.0 million, primarily to accelerate the development of its two lead portfolio companies, Vortex Biosciences and Wanda, towards significant value inflection milestones and exits. Neither the Placing nor the Additional Fundraising are underwritten.
A Circular setting out further details on the Placing, Additional Fundraising and the Rule 9 Waiver is expected to be posted to shareholders no later than 23 October 2015, with Admission expected to occur no later than 30 November 2015.
The Company has today separately released its half year results for the six months ended 30 June 2015
Details of the Fundraising
· Placing - Placing of 15,000,000 New Ordinary Shares at 120p each to raise approximately £18.0m before expenses by means of a placing by Investec Bank and Liberum
· Additional Fundraising - Up to 1,666,667 New Ordinary Shares at 120p to raise up to approximately £2.0 million. The Additional Fundraising will be by way of a private placing or subscription at the Directors' discretion, and is not open to the public
· Issue Price - The Issue Price of the New Ordinary Shares at 120 pence per Ordinary Share, represents a discount of 19.5 per cent. to the closing middle market share price of 149 pence on 30 September 2015
· Notice of General Meeting - Due to the size of the Placing, Shareholder approval is required which will be sought at the General Meeting
· Rule 9 Waiver - Given the level of investment by Woodford Investment Management LLP ("Woodford") in the proposed Placing, assuming the Placing receives all necessary approvals, it will result in Woodford owning more than 30 per cent. of the total voting rights of the Company. This investment requires a waiver by the Takeover Panel under Rule 9 of the Code and must be approved by Independent Shareholders under Rule 9 of the Code and such approval will be sought at the General Meeting
· The Directors unanimously recommend Shareholders to vote in favour of the Resolutions
Francois R. Martelet, M.D., Chief Executive Officer of NetScientific, said:
"Our core portfolio companies, led by Vortex and Wanda, have made significant progress over the past 12 months, as described in today's results. The proposed funding would make a real difference to the rate at which we can accelerate Vortex and Wanda and we recommend Shareholders to vote positively at the General Meeting".
-Ends-
For more information, please contact:
NetScientific plc |
|
|
François R. Martelet, M.D., CEO |
Tel: +44 (0)20 3514 1800 |
|
Peter Thoms, CFO |
|
|
|
|
|
Investec Bank plc (NOMAD, broker and joint bookrunner) |
Tel: +44 (0)20 7597 4000 |
|
Gary Clarence / Daniel Adams |
|
|
|
|
|
Liberum Capital Limited (joint bookrunner) |
Tel: +44 (0)20 3100 2000 |
|
David Parsons / Christopher Britton |
|
|
|
|
|
Instinctif Partners Melanie Toyne-Sewell Rosanna Forrest |
Tel: +44 (0)20 7457 2020 or netscientific@instinctif.com |
|
Investec Bank plc, which is authorised in the United Kingdom by the Prudential Regulatory Authority and regulated by the FCA and the Prudential Regulatory Authority, is acting exclusively for the Company and no other person in connection with the Placing. Investec Bank plc is not acting for the Company or anyone else in connection with the Additional Fundraising. Investec Bank plc's responsibilities as the Company's nominated adviser under the AIM Rules for Nominated Advisers are owed solely to the London Stock Exchange and are not owed to the Company or to any Director or to any person in respect of his decision to acquire Placing Shares or Additional Fundraising Shares in reliance on any part of this document. No representation or warranty, express or implied, is made by Investec Bank plc about any of the contents of this document and, without limiting the statutory rights of any person to whom this document is issued, no liability whatsoever is accepted by Investec Bank plc for the accuracy of any information or opinions contained in this document or for the omission of any material information. Investec Bank plc will not be offering advice nor will it be responsible for providing client protections to recipients of this document in respect of the Placing and Additional Fundraising.
Liberum Capital Limited, which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for the Company and no other person in connection with the Placing. Liberum Capital Limited is not acting for the Company or anyone else in connection with the Additional Fundraising. No representation or warranty, express or implied, is made by Liberum Capital Limited about any of the contents of this document and, without limiting the statutory rights of any person to whom this document is issued, no liability whatsoever is accepted by Liberum Capital Limited for the accuracy of any information or opinions contained in this document or for the omission of any material information. Liberum Capital Limited will not be offering advice nor will it be responsible for providing client protections to recipients of this document in respect of the Placing and Additional Fundraising.
Proposed Placing to raise approximately £18.0 million
Additional Fundraising to raise up to approximately £2.0 million
Proposed waiver of Rule 9 of The City Code on Takeovers and Mergers (the "Code")
Notice of General Meeting
1. Introduction
The Company has today announced that it is proposing to raise approximately £18.0 million (before expenses) by way of the Placing by Investec Bank and Liberum of New Ordinary Shares with existing and new institutional investors and to raise up to a further £2.0 million through the Additional Fundraising. The net funds from the Placing will primarily be used to accelerate the development of its two lead portfolio companies, Vortex Biosciences and Wanda, towards significant value inflection milestones and exits. In addition, NetScientific intends to manage, in a controlled manner, its other majority-owned assets and minority investments.
The Placing and Additional Fundraising is conditional, amongst other things, on the passing of the Resolutions (other than the Whitewash Resolution) by Shareholders and the passing of the Whitewash Resolution by Independent Shareholders at the General Meeting, notice of which will be set out in a circular to be posted to Shareholders ("Circular") as soon as possible after this Announcement. Neither the Placing nor the Additional Fundraising are underwritten.
Woodford is currently a beneficial holder of approximately 29.4 per cent. of the Company's current issued share capital. Woodford has agreed to subscribe for 12,500,000 New Ordinary Shares, being an amount that would increase its percentage holding of the Company immediately following the Placing to over 30 per cent. which, without a waiver of the obligations under Rule 9 of the Code ("Rule 9 Waiver"), would oblige Woodford (and any persons acting in concert with it) to make a general offer to Shareholders of the Company under Rule 9 of the Code (a "Rule 9 Offer").
Following Admission, it is expected that Woodford will have a shareholding of approximately 45.3 per cent of the Company's enlarged share capital, excluding any New Ordinary Shares that may be issued through the Additional Fundraising.
The Company will apply for a waiver of the requirement for Woodford to make a Rule 9 Offer under Note 1 to the Notes on Dispensations from Rule 9 of the Code, which states that when the issue of new securities in consideration for an acquisition or a cash subscription would otherwise result in an obligation to make a Rule 9 Offer, the Takeover Panel will normally grant a waiver if, inter alia, the shareholders of a company who are independent of the person who would otherwise be required to make an offer and any person acting in concert with him or her pass an ordinary resolution on a poll at a general meeting approving the proposals giving rise to the obligation to make a Rule 9 Offer and the Takeover Panel has agreed to such a waiver being sought.
There can be no guarantee that the Independent Shareholders will pass the Whitewash Resolution or that the Takeover Panel will grant the waiver of the requirement for Woodford to make a Rule 9 Offer in connection with the Placing. If the Rule 9 Waiver is not granted or the Whitewash Resolution is not passed, the Placing will not be able to proceed in its current form and the Company will seek to pursue a different funding structure. In order to provide the necessary funding to its portfolio companies, it is likely that the Company will accelerate fundraising in its key subsidiaries through third party investment. In addition, licensing and/or sale of the minority investment technologies will be considered in order to maximise value to shareholders.
The Directors who hold Existing Ordinary Shares intend to vote in favour of the Resolutions in respect of the Existing Ordinary Shares held by them and which represent, in aggregate, approximately 0.3 per cent. of the Company's current issued share capital.
The Circular convening the General Meeting will contain additional information on the Code matters relevant to the Placing.
2. Current trading
Today the Company announced its results for the six months ended 30 June 2015. For that six month period the Company is reporting unaudited revenues of £0.5 million and an after tax loss of £5.3 million. Cash on the balance sheet as at 30 June 2015 was £11.1 million. Progress in all of the Company's investments continues in line with the Board's expectations.
3. Summary of Vortex and Wanda
Vortex Biosciences
Vortex Biosciences is a US based cancer diagnostic company, developing a novel liquid biopsy diagnostic instrument for circulating tumour cell enrichment, collection and analysis. The technology enables researchers and clinicians to non-invasively to capture, analyse, identify, and enumerate tumour cells for use in downstream clinical applications such as genetic analysis, monitoring disease progression and drug treatment effectiveness.
One of the key milestones for Vortex will be the launch of the VTX-1 into clinical research labs, expected during 2016.
In 2015, Vortex hired additional engineers and scientists to complete the development of its VTX-1 instrument, which is scheduled for shipment to Beta sites by the end of 2015. Collaborations with key opinion leaders including UCLA, Stanford and Harvard, in the field has resulted in demand for the new Beta VTX-1. In addition, Vortex filed new patent applications and received grant in four of its ten patent families.
Wanda
Wanda is a US based company which provides a cloud-based clinical decision support software solution to help healthcare providers improve the quality of outpatient care and reduce the costs associated with managing chronic diseases.
Its software aims to reduce the economic burden of hospital readmissions by providing tools to monitor and manage patients with chronic diseases, initially patients with congestive heart failure. The platform technology builds upon a patented predictive analytics and knowledge engine that utilises information from in-home and remote monitoring devices used by patients.
Following successful pilots with Triventis Health since May, first revenues from pilot programmes are expected in Q4 2015.
As part of a focused effort on strengthening portfolio company management, Steve Curd was appointed CEO of Wanda on 14 September. He has more than 20 years' experience in driving growth in digital healthcare companies, commercialising products and delivering exits.
The key milestones for Wanda is patient uptake and Wanda is looking to accelerate this during 2016 and 2017.
4. Reasons for the Placing and Additional Fundraising and use of proceeds
The Directors believe that there is significant embedded value within its portfolio companies, in particular Vortex and Wanda, which require additional capital investment in order to reach value inflection milestones. The Group will focus on further funding Vortex and Wanda toward commercialisation and potential exit opportunities. In addition, NetScientific intends to manage, in a controlled manner, its other majority-owned assets and minority investments.
The Directors believe that the flexibility provided by a non-pre-emptive placing makes it the most appropriate fundraising structure for the Company at this time.
5. Principal Terms of the Placing
The Company has conditionally raised £18.0 million before expenses by the conditional Placing of 15,000,000 Placing Shares at the Issue Price to the Placees. The Placing is not underwritten.
The Placing is conditional, among other matters, upon:
(i) the passing of all of the Resolutions (other than the Whitewash Resolution) by Shareholders;
(ii) the Takeover Panel providing a Rule 9 Waiver, subject to the Whitewash Resolution being approved by Independent Shareholders;
(iii) the passing of the Whitewash Resolution by Independent Shareholders;
(iv) the Placing Agreement becoming or being declared unconditional in all respects and not having been terminated in accordance with its terms before Admission; and
(v) Admission becoming effective by no later than 8.00 a.m. on 13 November 2015 (or such later date as the Company, Investec Bank and Liberum may agree, provided that such date shall not extend beyond 8.00 a.m. on 30 November 2015). Admission may occur at an earlier date, which if achievable, will be set out in the Circular.
If any of the conditions are not satisfied (or waived), the Placing Shares will not be issued and all monies received from the Placees will be returned to them (at the Placees' risk and without interest) as soon as possible thereafter.
The Placing Shares are not being allotted subject to clawback. The Placing Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of their issue.
6. Principal Terms of the Additional Fundraising
In addition to the Placing, the Company is targeting a maximum further raise of £2.0 million (before expenses) by way of an Additional Fundraising of up to 1,666,667 New Ordinary Shares at the Issue Price. The Additional Fundraising will be by way of a private placing or subscription at the Directors' discretion, and is not open to the public. The Additional Fundraising will be available only to existing institutional or other investors which the Directors are satisfied can lawfully invest on a private placement basis.
The Additional Fundraising is not underwritten and neither Investec Bank nor Liberum is acting for the Company, or any other person, in connection with the Additional Fundraising.
The Additional Fundraising Shares will be allotted and issued fully paid and will, on issue, rank pari passu with the Existing Ordinary Shares in issue, including the right to receive, in full, all dividends and other distributions thereafter declared, made or paid after the date of issue together with all rights attaching to them and free from all liens, charges and encumbrances of any kind.
Related Party Transaction
The participation of Woodford in the Placing constitutes a related party transaction under the AIM Rules for Companies by virtue of Woodford being a substantial shareholder in the Company. The Directors consider, having consulted with Investec Bank, its nominated adviser, that the terms of the transaction are fair and reasonable in so far as its Shareholders are concerned.
Recommendation
The Directors believe that the Placing, Rule 9 Waiver and Additional Fundraising and the passing of the Resolutions are in the best interests of the Company and Shareholders, taken as a whole. Accordingly the Directors unanimously intend to recommend Shareholders (or Independent Shareholders as the case may be) vote in favour of the Resolutions, as they intend to do in respect of their aggregate beneficial holdings of 90,526 Ordinary Shares, representing 0.3 per cent of the Existing Ordinary Shares.
The Placing and Additional Fundraising are conditional, among other things, upon the passing of the Resolutions at the General Meeting. Shareholders should be aware that if the Resolutions are not approved at the General Meeting by the Shareholders or the Independent Shareholders (as applicable), the Placing and Additional Fundraising will not proceed.
Definitions
The following definitions apply throughout this document, unless the context requires otherwise:
"Act" "Additional Fundraising"
|
Companies Act 2006 (as amended) the issue, separate to the Placing, of up to a further 1,666,667 New Ordinary Shares to existing institutional or other investors to whom such shares can lawfully be offered on a private placement basis |
"Additional Fundraising Shares" |
the New Ordinary Shares to be issued pursuant to the Additional Fundraising |
"Admission" |
the admission of the New Ordinary Shares to trading on AIM in accordance with the AIM Rules for Companies |
"AIM Rules for Companies" |
the AIM Rules for Companies and guidance notes as published by the London Stock Exchange from time to time |
"AIM" |
the AIM market operated by London Stock Exchange |
"Board" or "Directors" |
the directors of the Company as at the date of this document |
"Business Day" |
a day other than a Saturday, Sunday or public holiday in England when banks in London are open for business |
"Circular" |
as defined in this Announcement |
"Code" |
The City Code on Takeovers and Mergers |
"Company" or "NetScientific" |
NetScientific plc |
"CREST member" |
a person who has been admitted to CREST as a system-member (as defined in the CREST Manual) |
"CREST Regulations" |
the Uncertificated Securities Regulations 2001 (SI 2001/3755) (as amended) |
"CREST" |
the relevant system (as defined in the CREST Regulations) in respect of which Euroclear is the operator (as defined in the CREST Regulations) |
"Enlarged Share Capital" |
the entire issued share capital of the Company following the issue of New Ordinary Shares pursuant to the Fundraising, assuming the maximum number of Additional Fundraising Shares are issued |
"Euroclear" |
Euroclear UK & Ireland Limited |
"Existing Ordinary Shares" |
the 35,902,020 Ordinary Shares in issue on the date of this document |
"FCA" |
the Financial Conduct Authority of the UK |
"FSMA" |
Financial Services and Markets Act 2000 (as amended) |
"Fundraising" |
the Placing and the Additional Fundraising |
"General Meeting" |
the General Meeting of the Company, notice of which will be set out in the Circular |
"Group" |
the Company and its subsidiaries |
"Independent Shareholders" |
all Shareholders other than Woodford (and anyone acting in concert with it) |
"Investec Bank" |
Investec Bank plc |
"Liberum" |
Liberum Capital Limited |
"London Stock Exchange" |
London Stock Exchange plc |
"New Ordinary Shares" |
the new Ordinary Shares being issued in relation to the Fundraising |
"Notice of General Meeting" |
the notice convening the General Meeting to be set out in the Circular |
"Issue Price" |
120 pence per New Ordinary Share |
"Ordinary Shares" |
ordinary shares of 5p each in the capital of the Company |
"Placees" |
subscribers for Placing Shares |
"Placing" |
the placing of 15,000,000 New Ordinary Shares at 120 pence per share, the details of which are set out in the Circular |
"Placing Agreement" |
the agreement entered into between the Company, Investec Bank and Liberum in respect of the Placing dated 1 October 2015 |
"Placing Shares" |
the 15,000,000 New Ordinary Shares to be issued pursuant to the Placing |
"Resolutions" |
the resolutions to be proposed at the General Meeting as set out in the Notice of General Meeting |
"Rule 9 Offer" |
as defined in this Announcement |
"Rule 9 Waiver" |
as defined in this Announcement |
"Securities Act" |
US Securities Act of 1933 (as amended) |
"Shareholders" |
the holders of Existing Ordinary Shares |
"Takeover Panel" |
the Panel on Takeovers and Mergers |
"United Kingdom" or "UK" |
the United Kingdom of Great Britain and Northern Ireland |
"United States", "United States of America" or "US" |
the United States of America, its territories and possessions, any state of the United States of America and the District of Columbia and all areas subject to its jurisdiction |
"Vortex" or "Vortex Biosciences" |
Vortex Biosciences, Inc. |
"Wanda" |
Wanda, Inc. |
"Whitewash Resolution" |
the resolution to be proposed to Independent Shareholders as set out in the Notice of General Meeting to approve the Rule 9 Waiver |
"Woodford" |
as defined in this Announcement |
APPENDIX - TERMS AND CONDITIONS OF THE PLACING
IMPORTANT INFORMATION FOR INVITED PLACEES ONLY REGARDING THE PLACING.
THIS ANNOUNCEMENT, INCLUDING THIS APPENDIX AND THE INFORMATION CONTAINED HEREIN (TOGETHER THE "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, THE REPUBLIC OF IRELAND, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT HAS NOT BEEN APPROVED BY THE LONDON STOCK EXCHANGE, NOR IS IT INTENDED THAT IT WILL BE SO APPROVED.
MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS DIRECTED ONLY AT: (A) PERSONS IN MEMBER STATES OF THE EUROPEAN ECONOMIC AREA ("EEA") WHO ARE QUALIFIED INVESTORS AS DEFINED IN SECTION 86(7) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000, AS AMENDED ("QUALIFIED INVESTORS"), BEING PERSONS FALLING WITHIN THE MEANING OF ARTICLE 2(1)(e) OF DIRECTIVE 2003/71/EC AS AMENDED, INCLUDING BY THE 2010 PROSPECTUS DIRECTIVE AMENDING DIRECTIVE (DIRECTIVE 2010/73/EC) AND TO THE EXTENT IMPLEMENTED IN THE RELEVANT MEMBER STATE (THE "PROSPECTUS DIRECTIVE"); AND (B) IN THE UNITED KINGDOM, QUALIFIED INVESTORS WHO ARE PERSONS WHO (I) HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) (INVESTMENT PROFESSIONALS) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER"); (II) ARE PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC.) OF THE ORDER; OR (III) ARE PERSONS TO WHOM IT MAY OTHERWISE BE LAWFULLY COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS").
THIS ANNOUNCEMENT AND THE INFORMATION IN IT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. PERSONS DISTRIBUTING THIS ANNOUNCEMENT MUST SATISFY THEMSELVES THAT IT IS LAWFUL TO DO SO. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS. THIS ANNOUNCEMENT DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN NETSCIENTIFIC PLC.
THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE INTO THE UNITED STATES. THE PLACING SHARES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT 1933, AS AMENDED (THE "SECURITIES ACT") OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR JURISDICTION OF THE UNITED STATES, AND MAY NOT BE OFFERED, SOLD OR TRANSFERRED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. SUBJECT TO CERTAIN EXCEPTIONS AND AT THE SOLE DISCRETION OF THE COMPANY, THE PLACING SHARES ARE BEING OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES IN "OFFSHORE TRANSACTIONS" WITHIN THE MEANING OF, AND IN ACCORDANCE WITH, REGULATION S UNDER THE SECURITIES ACT AND OTHERWISE IN ACCORDANCE WITH APPLICABLE LAWS. NO PUBLIC OFFERING OF THE PLACING SHARES IS BEING MADE IN THE UNITED STATES, THE UNITED KINGDOM OR ELSEWHERE. NO MONEY, SECURITIES OR OTHER CONSIDERATION FROM ANY PERSON INSIDE THE UNITED STATES IS BEING SOLICITED AND, IF SENT IN RESPONSE TO THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT, WILL NOT BE ACCEPTED.
EACH PLACEE SHOULD CONSULT WITH ITS ADVISERS AS TO LEGAL, TAX, BUSINESS AND RELATED ASPECTS OF AN INVESTMENT IN PLACING SHARES. THE DISTRIBUTION OF THIS ANNOUNCEMENT, ANY PART OF IT OR ANY INFORMATION CONTAINED IN IT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS, AND ANY PERSON INTO WHOSE POSSESSION THIS ANNOUNCEMENT, ANY PART OF IT OR ANY INFORMATION CONTAINED IN IT COMES SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE, SUCH RESTRICTIONS.
No action has been taken by the Company, Investec Bank, Liberum or any of their respective affiliates, agents, directors, officers or employees that would permit an offer of the Placing Shares or possession or distribution of this Announcement or any other offering or publicity material relating to such Placing Shares in any jurisdiction where action for that purpose is required.
This Announcement or any part of it does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in the United States (including its territories and possessions, any state of the United States and the District of Columbia), Canada, the Republic of Ireland, Australia, the Republic of South Africa, Japan or any other jurisdiction in which the same would be unlawful. No public offering of the Placing Shares is being made in any such jurisdiction.
All offers of the Placing Shares will be made pursuant to an exemption under the Prospectus Directive from the requirement to produce a prospectus. In the United Kingdom, this Announcement is being directed solely at persons in circumstances in which section 21(1) of the Financial Services and Markets Act 2000 (as amended) (the "FSMA") does not apply.
The Placing Shares have not been approved or disapproved by the US Securities and Exchange Commission, any state securities commission or other regulatory authority in the United States, nor have any of the foregoing authorities passed upon or endorsed the merits of the Placing or the accuracy or adequacy of this Announcement. Any representation to the contrary is a criminal offence in the United States. The relevant clearances have not been, nor will they be, obtained from the securities commission of any province or territory of Canada, no prospectus has been lodged with, or registered by, the Australian Securities and Investments Commission or the Japanese Ministry of Finance; the relevant clearances have not been, and will not be, obtained for the South Africa Reserve Bank or any other applicable body in the Republic of South Africa in relation to the Placing Shares and the Placing Shares have not been, nor will they be, registered under or offering in compliance with the securities laws of any state, province or territory of Australia, Canada, Japan or the Republic of South Africa. Accordingly, the Placing Shares may not (unless an exemption under the relevant securities laws is applicable) be offered, sold, resold or delivered, directly or indirectly, in or into Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction outside the United Kingdom.
Persons (including, without limitation, nominees and trustees) who have a contractual right or other legal obligations to forward a copy of this Announcement should seek appropriate advice before taking any action.
This Announcement should be read in its entirety. In particular, you should read and understand the information provided in this "Important Information" section of this Announcement.
By participating in the Placing, each person who is invited to and who chooses to participate in the Placing (a "Placee") will be deemed to have read and understood this Announcement in its entirety, to be participating, making an offer and acquiring Placing Shares on the terms and conditions contained herein and to be providing the representations, warranties, indemnities, acknowledgements and undertakings contained in this Appendix.
In particular, each such Placee represents, warrants, undertakes, agrees and acknowledges (amongst other things) that:
No prospectus
No prospectus or other offering document has been or will be submitted to be approved by the FCA in relation to the Placing or the Placing Shares and Placees' commitments will be made solely on the basis of the information contained in this Announcement and any information publicly announced through a Regulatory Information Service (as defined in the AIM Rules for Companies (the "AIM Rules")) by or on behalf of the Company on or prior to the date of this Announcement (the "Publicly Available Information") and subject to any further terms set forth in the contract note to be sent to individual Placees.
Each Placee, by participating in the Placing, agrees that the content of this Announcement is exclusively the responsibility of the Company and confirms that it has neither received nor relied on any information (other than the Publicly Available Information), representation, warranty or statement made by or on behalf of Investec Bank, Liberum, the Company or any other person and none of Investec Bank, Liberum, the Company or any other person acting on such person's behalf nor any of their respective affiliates has or shall have any liability for any Placee's decision to participate in the Placing based on any other information, representation, warranty or statement. Each Placee acknowledges and agrees that it has relied on its own investigation of the business, financial or other position of the Company in accepting a participation in the Placing. Nothing in this paragraph shall exclude the liability of any person for fraudulent misrepresentation.
Details of the Placing Agreement and the Placing Shares
Investec Bank and Liberum (together the "Banks" and each a "Bank") have today entered into a placing agreement (the "Placing Agreement") with the Company under which, on the terms and subject to the conditions set out in the Placing Agreement, each of the Banks, as agent for and on behalf of the Company, has agreed to use their reasonable endeavours to procure Placees for the Placing Shares at the Placing Price.
The Placing Shares will, when issued, be subject to the articles of association of the Company and credited as fully paid and will rank pari passu in all respects with the existing issued ordinary shares of five pence per share ("Ordinary Shares") in the capital of the Company, including the right to receive all dividends and other distributions declared, made or paid in respect of such Ordinary Shares after the date of issue of the Placing Shares.
As part of the Placing, the Company has agreed that it will not for a period of 90 days after Admission (save pursuant to the Additional Fundraising as defined in this Announcement), offer, issue, sell, contract to sell, issue options in respect of or otherwise dispose of any securities of the Company (or any interest therein or in respect thereof) or any other securities exchangeable for, or convertible into, or substantially similar to, Ordinary Shares or enter into any transaction having substantially the same effect or agree to do any of the foregoing other than with the prior written consent of Investec Bank and Liberum (such consent not to be unreasonably withheld or delayed) or in relation to certain permitted staff share scheme grants.
Application for admission to trading
Application will be made to the London Stock Exchange for admission of the Placing Shares to trading on AIM.
It is expected that Admission will take place no later than 30 November 2015 and that dealings in the Placing Shares on AIM will commence at the same time.
Principal terms of the Placing
2. Liberum is acting as joint broker to the Placing, as agent for and on behalf of the Company. Liberum is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for the Company and no one else in connection with the matters referred to in this Announcement and will not be responsible to anyone other than the Company for providing the protections afforded to the customers of Liberum or for providing advice in relation to the matters described in this Announcement.
Registration and Settlement
If Placees are allocated any Placing Shares in the Placing they will be sent a contract note or electronic confirmation by the relevant Bank, as soon as it is able which will confirm the number of Placing Shares allocated to them, the Placing Price and the aggregate amount owed by them to the relevant Bank.
Each Placee will be deemed to agree that it will do all things necessary to ensure that delivery and payment is completed as directed by the relevant Bank in accordance with either the standing CREST or certificated settlement instructions which they have in place with the relevant Bank.
Settlement of transactions in the Placing Shares (ISIN: GB00B9F4MT28) following Admission will take place within the CREST system, subject to certain exceptions. Settlement through CREST is expected to take place on 13 November 2015 unless otherwise notified by the Banks and Admission is expected to occur no later than 8.00 a.m. on 13 November 2015 unless otherwise notified by the Banks. Admission and Settlement may occur at an earlier date, which if achievable, will be set out in the Circular. Settlement will be on a delivery versus payment basis. However, in the event of any difficulties or delays in the admission of the Placing Shares to CREST or the use of CREST in relation to the Placing, the Company and each of the Banks may agree that the Placing Shares should be issued in certificated form. Each of the Banks reserves the right to require settlement for the Placing Shares, and to deliver the Placing Shares to Placees, by such other means as they deem necessary if delivery or settlement to Placees is not practicable within the CREST system or would not be consistent with regulatory requirements in a Placee's jurisdiction.
Interest is chargeable daily on payments not received from Placees on the due date in accordance with the arrangements set out above, in respect of either CREST or certificated deliveries, at the rate of 2 percentage points above prevailing LIBOR as determined by the Banks.
Each Placee is deemed to agree that if it does not comply with these obligations, the Banks may sell any or all of their Placing Shares on their behalf and retain from the proceeds, for the Bank's own account and benefit, an amount equal to the aggregate amount owed by the Placee plus any interest due. The relevant Placee will, however, remain liable for any shortfall below the amount owed by it and for any stamp duty or stamp duty reserve tax (together with any interest or penalties) which may arise upon the sale of their Placing Shares on their behalf.
If Placing Shares are to be delivered to a custodian or settlement agent, Placees must ensure that, upon receipt, the conditional contract note is copied and delivered immediately to the relevant person within that organisation. Insofar as Placing Shares are registered in a Placee's name or that of its nominee or in the name of any person for whom a Placee is contracting as agent or that of a nominee for such person, such Placing Shares should, subject as provided below, be so registered free from any liability to United Kingdom stamp duty or stamp duty reserve tax. Placees will not be entitled to receive any fee or commission in connection with the Placing.
Conditions of the Placing
The Placing is conditional upon the Placing Agreement becoming unconditional and not having been terminated in accordance with its terms.
The obligations of each of the Banks under the Placing Agreement are, and the Placing is, conditional upon, inter alia:
(all conditions to the obligations of each of the Banks included in the Placing Agreement being together, the "conditions").
If any of the conditions set out in the Placing Agreement are not fulfilled or, where permitted, waived in accordance with the Placing Agreement within the stated time periods (or such later time and/or date as the Company and the Banks may agree, provided that the time for satisfaction of the condition set out in (g) above shall not be extended beyond 8.00 a.m. on 30 November 2015), or the Placing Agreement is terminated in accordance with its terms, the Placing will lapse and the Placee's rights and obligations shall cease and terminate at such time and each Placee agrees that no claim can be made by or on behalf of the Placee (or any person on whose behalf the Placee is acting) in respect thereof.
By participating in the Placing, each Placee agrees that its rights and obligations cease and terminate only in the circumstances described above and under "Termination of the Placing" below and will not be capable of rescission or termination by it.
Certain conditions may be waived in whole or in part by the Banks, acting jointly, in their absolute discretion by notice in writing to the Company and the Banks may also agree in writing with the Company to extend the time for satisfaction of any condition. Any such extension or waiver will not affect Placees' commitments as set out in this Announcement.
Either of the Banks may terminate the Placing Agreement in certain circumstances, details of which are set out below.
None of the Banks, the Company or any of their respective affiliates, agents, directors, officers, employees shall have any liability to any Placee (or to any other person whether acting on behalf of a Placee or otherwise) in respect of any decision any of them may make as to whether or not to waive or to extend the time and/or date for the satisfaction of any condition to the Placing nor for any decision any of them may make as to the satisfaction of any condition or in respect of the Placing generally and by participating in the Placing each Placee agrees that any such decision is within the absolute discretion of the Banks
Termination of the Placing
Either of the Banks may terminate the Placing Agreement, in accordance with its terms, at any time prior to Admission if, inter alia:
If the Placing Agreement is terminated in accordance with its terms, the rights and obligations of each Placee in respect of the Placing as described in this Announcement shall cease and terminate at such time and no claim can be made by any Placee in respect thereof.
By participating in the Placing, each Placee agrees with the Company and the Banks that the exercise by the Company or the Banks of any right of termination or any other right or other discretion under the Placing Agreement shall be within the absolute discretion of the Company or the Banks and that neither of the Company nor the Banks need make any reference to such Placee and that none of the Banks, the Company, or any of their respective affiliates, agents, directors, officers or employees shall have any liability to such Placee (or to any other person whether acting on behalf of a Placee or otherwise) whatsoever in connection with any such exercise.
By participating in the Placing, each Placee agrees that its rights and obligations terminate only in the circumstances described above and under the "Conditions of the Placing" section above and will not be capable of rescission or termination by it after the issue by the relevant Bank of a contract note confirming each Placee's allocation and commitment in the Placing.
Representations, warranties and further terms
By participating in the Placing, each Placee (and any person acting on such Placee's behalf) represents, warrants, acknowledges and agrees (for itself and for any such prospective Placee) that (save where the Banks expressly agree in writing to the contrary):
The representations, warranties, acknowledgements and undertakings contained in this Appendix are given to each of the Banks for itself and on behalf of the Company and are irrevocable.
Each Placee and any person acting on behalf of the Placee acknowledges that the Banks do not owe any fiduciary or other duties to any Placee in respect of any representations, warranties, undertakings, acknowledgements, agreements or indemnities in the Placing Agreement.
Each Placee and any person acting on behalf of the Placee acknowledges and agrees that the Banks may (at their absolute discretion) satisfy their obligations to procure Placees by itself agreeing to become a Placee in respect of some or all of the Placing Shares or by nominating any connected or associated person to do so.
When a Placee or any person acting on behalf of the Placee is dealing with the relevant Bank, any money held in an account with the relevant Bank on behalf of the Placee and/or any person acting on behalf of the Placee will not be treated as client money within the meaning of the relevant rules and regulations of the FCA made under FSMA. Each Placee acknowledges that the money will not be subject to the protections conferred by the client money rules: as a consequence this money will not be segregated from the relevant Bank's money (as applicable) in accordance with the client money rules and will be held by it under a banking relationship and not as trustee.
References to time in this Announcement are to London time, unless otherwise stated.
All times and dates in this Announcement may be subject to amendment.
No statement in this Announcement is intended to be a profit forecast, and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.
The price of shares and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser.
The Placing Shares to be issued or sold pursuant to the Placing will not be admitted to trading on any stock exchange other than the London Stock Exchange.
Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.